Steven Cohen’s EW Holdings & Trades

First Buy
Q3 2014
Duration Held
45 Quarters
Largest Add
Q1 2024
+2.97 M Shares
Current Position
732,058 Shares
$56.93 M Value

Steven Cohen's EW Position Overview

Steven Cohen (via Point72 Asset Management, L.P.) currently holds 732,058 shares of Edwards Lifesciences Corporation (EW) worth $56.93 M, representing 0.10% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 45 quarters.

Based on 13F filings since 2013, Steven Cohen has maintained a long-term strategic position in EW, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2024, adding 2.95 M shares. Largest reduction occurred in Q2 2024, reducing 2.53 M shares.

Analysis based on 13F filings available since 2013 Q2

Steven Cohen's Edwards Lifesciences Corporation (EW) Holding Value Over Time

Track share changes against reported price movement

Quarterly Edwards Lifesciences Corporation (EW) Trades by Steven Cohen

Period Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q3 2014 +1.24 M New Buy 1.24 M $17.03
Q4 2014 -1.24 M Sold Out 1.24 M $0.00
Q1 2015 +1.44 M New Buy 1.44 M $23.74
Q2 2015 -397,200 Reduce 27.65% 1.04 M $23.74
Q3 2015 +360,000 Add 34.64% 1.4 M $23.69
Q4 2015 -949,800 Reduce 67.88% 449,400 $26.33
Q1 2016 -408,300 Reduce 90.85% 41,100 $29.39
Q2 2016 +541,500 Add 1317.52% 582,600 $33.24
Q3 2016 +431,100 Add 74.00% 1.01 M $40.19
Q4 2016 +415,500 Add 40.99% 1.43 M $31.23
Q1 2017 -1.09 M Reduce 76.26% 339,225 $31.36
Q2 2017 +999,975 Add 294.78% 1.34 M $39.41
Q3 2017 +84,285 Add 6.29% 1.42 M $36.44
Q4 2017 -1.03 M Reduce 72.60% 390,000 $37.57
Q1 2018 +210,000 Add 53.85% 600,000 $46.51
Q2 2018 -600,000 Sold Out 600,000 $0.00
Q3 2018 +13,800 New Buy 13,800 $58.04
Q4 2018 +184,800 Add 1339.13% 198,600 $51.06
Q1 2019 -33,540 Reduce 16.89% 165,060 $63.78
Q2 2019 -130,857 Reduce 79.28% 34,203 $61.57
Q3 2019 +120,120 Add 351.20% 154,323 $73.30
Q4 2019 -75,888 Reduce 49.17% 78,435 $77.76
Q1 2020 +164,112 Add 209.23% 242,547 $62.87
Q2 2020 +244,137 Add 100.66% 486,684 $69.11
Q3 2020 -367,269 Reduce 75.46% 119,415 $79.82
Q4 2020 -119,415 Sold Out 119,415 $0.00
Q1 2021 +579,142 New Buy 579,142 $83.64
Q2 2021 -579,142 Sold Out 579,142 $0.00
Q1 2023 +385 New Buy 385 $82.68
Q2 2023 -385 Sold Out 385 $0.00
Q3 2023 +22,199 New Buy 22,199 $69.28
Q4 2023 -22,199 Sold Out 22,199 $0.00
Q1 2024 +2.97 M New Buy 2.97 M $95.56
Q2 2024 -2.53 M Reduce 85.05% 444,162 $92.37
Q3 2024 -444,162 Sold Out 444,162 $0.00
Q4 2024 +588,206 New Buy 588,206 $74.03
Q1 2025 +880,527 Add 149.70% 1.47 M $72.48
Q2 2025 +1.57 M Add 106.94% 3.04 M $78.21
Q3 2025 -2.31 M Reduce 75.91% 732,058 $77.77

Steven Cohen's Edwards Lifesciences Corporation Investment FAQs

Steven Cohen first purchased Edwards Lifesciences Corporation (EW) in Q3 2014, acquiring 1,237,800 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Steven Cohen has held Edwards Lifesciences Corporation (EW) for 45 quarters since Q3 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Steven Cohen's largest addition to Edwards Lifesciences Corporation (EW) was in Q1 2024, adding 2,970,804 shares worth $283.89 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

According to the latest 13F filing for Q3 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 732,058 shares of Edwards Lifesciences Corporation (EW), valued at approximately $56.93 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

As of the Q3 2025 filing, Edwards Lifesciences Corporation (EW) represents approximately 0.10% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Steven Cohen's peak holding in Edwards Lifesciences Corporation (EW) was 3,039,381 shares, as reported at the end of Q2 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.